Best Alternative to Bupropion When Already on an SSRI
When a patient already on an SSRI requires an alternative to bupropion, switch to mirtazapine or add/switch to duloxetine/venlafaxine (SNRIs), as these have demonstrated efficacy as second-line options with distinct side effect profiles that may address treatment-resistant depression. 1
Rationale for Recommendation
The American College of Physicians guidelines establish that no second-generation antidepressant demonstrates superior efficacy over others for major depressive disorder 1. However, when bupropion is not an option and the patient is already on an SSRI with inadequate response, the evidence supports specific strategies:
Primary Options:
Mirtazapine emerges as the strongest alternative because:
- Faster onset of action compared to SSRIs (statistically significant improvement within 1-2 weeks versus 4 weeks) 1
- Different mechanism (alpha-2 adrenoceptor antagonist enhancing norepinephrine and serotonin) 2
- Particularly useful if the patient has insomnia or poor appetite, as sedation and weight gain are predictable side effects 1
SNRIs (Duloxetine or Venlafaxine) are equally valid alternatives:
- Duloxetine: 60 mg once daily, simple dosing, effective for comorbid pain conditions 3
- Venlafaxine: Requires titration to 150-225 mg/d over 2-4 weeks 3
- Both have dual norepinephrine/serotonin activity, offering a different mechanism than pure SSRIs 1
Evidence from Second-Line Treatment Studies
The STAR*D trial—the highest quality evidence for treatment-resistant depression—found no difference in efficacy when switching between second-generation antidepressants (bupropion, sertraline, or venlafaxine), with approximately 25% of patients achieving remission after switching 1, 4. This supports that the choice should be driven by side effect profiles and patient-specific factors rather than efficacy differences.
Critical Side Effect Considerations
Sexual Dysfunction Profile:
- Bupropion has the lowest rates of sexual dysfunction among antidepressants (significantly lower than fluoxetine or sertraline) 1, 5
- Paroxetine has the highest rates of sexual dysfunction 1
- If sexual dysfunction was the reason for considering alternatives to the current SSRI, mirtazapine or switching to a different SSRI with lower sexual dysfunction rates (not paroxetine) would be preferable
Other Key Adverse Effects:
- Mirtazapine: Sedation (most common), weight gain, increased appetite 1, 2
- Venlafaxine: Higher nausea/vomiting rates, potential blood pressure increases, cardiac conduction concerns 3, 1
- Duloxetine: Nausea (reduced by starting at 30 mg for 1 week), no significant cardiac effects 3
Practical Algorithm
If patient is on SSRI with partial response:
- Consider augmentation with mirtazapine rather than switching (evidence shows similar efficacy between switching and augmenting strategies) 4
- If switching is preferred, choose based on:
- Insomnia/poor appetite present → Mirtazapine
- Comorbid pain/neuropathy → Duloxetine
- Need faster onset → Mirtazapine (1-2 weeks vs 4-6 weeks)
If patient is on SSRI with no response:
- Switch to mirtazapine, duloxetine, or venlafaxine
- Allow adequate trial: 6-8 weeks at therapeutic dose 1
Important Caveats
Suicidality monitoring: All second-generation antidepressants carry similar suicide risk, but SSRIs show increased risk for nonfatal suicide attempts compared to placebo 1. Monitor closely in first 1-2 weeks, especially in patients under 25 years 1, 6
Seizure risk: While bupropion has weak evidence for increased seizure risk 1, this is not a concern with mirtazapine or SNRIs
Drug interactions: Venlafaxine may increase cardiovascular events; duloxetine is generally safer 3, 1
Discontinuation rates: Nausea/vomiting are the most common reasons for stopping antidepressants across all classes 1
What NOT to Do
Do not simply switch to another SSRI if the patient is already on an SSRI—38% of patients don't respond to initial treatment and 54% don't achieve remission 1. Switching within the same class offers no mechanistic advantage. Choose an agent with a different mechanism of action (mirtazapine or SNRI) to maximize the chance of response.